Our research suggests that SGLT2 inhibitors may increase the risk of obsessive-compulsive disorder through some mechanism beyond their hypoglycemic effect, indicating that the use of SGLT2 inhibitors may be an important risk factor for obsessive-compulsive disorder. Here, SLC5A2 is linked to obsessive-compulsive disorder.